Jefferies Financial Group Inc. Cuts Stock Holdings in Charles River Laboratories International, Inc. $CRL

Jefferies Financial Group Inc. lowered its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 43.6% in the 3rd quarter, Holdings Channel.com reports. The fund owned 5,000 shares of the medical research company’s stock after selling 3,872 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Charles River Laboratories International were worth $782,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in CRL. Neo Ivy Capital Management bought a new position in Charles River Laboratories International in the 2nd quarter valued at approximately $29,000. Rothschild Investment LLC increased its holdings in shares of Charles River Laboratories International by 82.4% in the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock worth $29,000 after purchasing an additional 84 shares in the last quarter. Atlantic Union Bankshares Corp purchased a new position in shares of Charles River Laboratories International in the third quarter worth $31,000. Geneos Wealth Management Inc. lifted its holdings in shares of Charles River Laboratories International by 98.0% during the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 145 shares in the last quarter. Finally, Allworth Financial LP lifted its holdings in shares of Charles River Laboratories International by 172.7% during the second quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock valued at $45,000 after purchasing an additional 190 shares in the last quarter. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Stock Down 9.9%

NYSE CRL opened at $152.22 on Friday. Charles River Laboratories International, Inc. has a 52 week low of $91.86 and a 52 week high of $228.88. The company has a quick ratio of 1.02, a current ratio of 1.29 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $7.49 billion, a P/E ratio of -51.43, a price-to-earnings-growth ratio of 2.89 and a beta of 1.64. The stock’s 50-day moving average price is $192.53 and its 200-day moving average price is $180.94.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 18th. The medical research company reported $2.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.33 by $0.06. The company had revenue of $994.23 million during the quarter, compared to the consensus estimate of $986.98 million. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The firm’s revenue was down .8% on a year-over-year basis. During the same period in the previous year, the company posted $2.66 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. On average, equities research analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Analyst Upgrades and Downgrades

CRL has been the subject of several research analyst reports. Evercore lifted their price objective on Charles River Laboratories International from $250.00 to $260.00 and gave the stock an “outperform” rating in a report on Tuesday, January 13th. Robert W. Baird set a $193.00 target price on shares of Charles River Laboratories International in a research note on Thursday, February 19th. UBS Group raised their price target on shares of Charles River Laboratories International from $170.00 to $175.00 and gave the company a “neutral” rating in a report on Wednesday, February 25th. Argus set a $200.00 price objective on shares of Charles River Laboratories International in a report on Monday, November 17th. Finally, Bank of America upgraded shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price objective on the stock in a research report on Monday, December 15th. Ten equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $203.57.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.